HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preoperative nomogram predicting 12-year probability of metastatic renal cancer - evaluation in a contemporary cohort.

AbstractOBJECTIVES:
Preoperative models, based on patient and tumor characteristics, predict risk for adverse outcomes after nephrectomy. Changes in renal tumor characteristics over the last decades, warrant further evaluation using contemporary cohorts. We aimed to validate a previously published preoperative nomogram predicting 12-year metastasis-free probability after nephrectomy for localized renal tumors in a contemporary cohort.
PATIENTS AND METHODS:
After obtaining institutional review board approval, data of 1,760 patients who underwent nephrectomy for a localized renal mass between 2005 and 2011 were reviewed. Preoperative images were evaluated for the presence of tumor necrosis, lymphadenopathy, and tumor size. The study outcome was metastatic-free probability. Model discrimination was assessed with Gönen and Heller's concordance probability estimate, and calibration was evaluated.
RESULTS:
The cohort included 1,102 male and 658 female patients with a median age of 60 years. Most patients presented incidentally (84%). On imaging, 3% had evidence of lymphadenopathy, 55% had necrosis and median tumor diameter was 3.7 cm (interquartile range [IQR]: 2.5, 5.5). Median follow-up in non-metastatic patients was 7.7 years (IQR: 5.3, 9.7). Estimated 12-year metastatic-free probability was 88% (86%-90%). The model showed strong discrimination (concordance probability estimate [CPE]: 0.77), and fair calibration. The time-dependent receiver operating characteristic (ROC) curves showed strong discrimination at all-time points and the area under the curve (AUC) for year 12 was 0.83 (95% Confidence Interval: 0.78-0.89).
CONCLUSIONS:
We validated the preoperative nomogram of 12-year metastasis-free probability in a contemporary cohort despite different tumor characteristics. Future studies should evaluate the role of preoperative risk stratification in patient selection for neoadjuvant treatment.
AuthorsRoy Mano, Cihan Duzgol, Maz Ganat, Debra A Goldman, Kyle A Blum, Andrew W Silagy, Aleksandra Walasek, Alejandro Sanchez, Renzo G DiNatale, Julian Marcon, Mahyar Kashan, Maria F Becerra, Nicole Benfante, Jonathan A Coleman, Michael W Kattan, Paul Russo, Oguz Akin, Irina Ostrovnaya, A Ari Hakimi
JournalUrologic oncology (Urol Oncol) Vol. 38 Issue 11 Pg. 853.e1-853.e7 (11 2020) ISSN: 1873-2496 [Electronic] United States
PMID32900625 (Publication Type: Journal Article, Validation Study)
CopyrightCopyright © 2020 Elsevier Inc. All rights reserved.
Topics
  • Aged
  • Cohort Studies
  • Female
  • Forecasting
  • Humans
  • Kidney Neoplasms (pathology, surgery)
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Nephrectomy
  • Nomograms
  • Preoperative Period
  • Probability
  • Retrospective Studies
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: